Young adults with gastrointestinal and neuroendocrine cancers
YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs (YOUNGSTER).
This study is trying to gather samples from young adults with gastrointestinal and neuroendocrine cancers to learn more about their specific needs and improve treatment options for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years to 39 Years |
| Sex | All |
| Sponsor | European Institute of Oncology Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06337760 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a platform for collecting biological samples from young adults diagnosed with gastrointestinal and neuroendocrine cancers. It focuses on identifying predictive and prognostic biomarkers that can help in understanding the unique characteristics and needs of this patient population. The study includes patients aged 18 to 39 years with various types of carcinomas and neuroendocrine neoplasms, regardless of tumor stage or grade. By addressing the underrepresentation of young adults in clinical studies, the research seeks to improve knowledge about risk factors and treatment outcomes for these cancers.
Who should consider this trial
Good fit: Ideal candidates for this study are young adults aged 18 to 39 who have been diagnosed with gastrointestinal or neuroendocrine cancers.
Not a fit: Patients diagnosed with cancer at age 40 or older will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better-targeted treatments and improved outcomes for young adults with gastrointestinal and neuroendocrine cancers.
How similar studies have performed: While there is limited research specifically targeting young adults with these cancers, studies focusing on biomarker identification in cancer have shown promise in other populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age at diagnosis from18 to 39 years of age * Carcinoma (without limitations for histologic subtypes) from any primary sites: esophagus, stomach, pancreas, biliary tract, liver, small bowel, colon, rectum, anus and cancer of unknown origin * Neuroendocrine neoplasm (NEN) from Gastroenteropancreatic GEP or lung/thymus origin * Tumors at any stage at the first visit * Tumors of any grade * Histological diagnosis obtained within two years from the time of enrollment or willingness to undergo bioptic procedure for diagnosis Exclusion Criteria: * Age at diagnosis \> 39 years old
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Francesca Spada, MD — Istituto Europeo di Oncologia
- Study coordinator: Lorenzo Gervaso, MD
- Email: divisione.gastrointestinale@ieo.it
- Phone: +390257489258
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.